Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women

Osteoporosis International

Volumn 9, Issue 4, 1999, Pages 358-366

  Cooper, C ^a,f   Stakkestad, J A ^b   Radowicki, S ^c   Hardy, P ^d   Pilate, C ^d   Dain, M P ^d   Delmas, P D ^e  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b CECOR AS   (Norway)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d SANOFI   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Bone turnover; Menopause; Transdermal estradiol

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; DYDROGESTERONE; ESTRADIOL; OSTEOCALCIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; BLOOD LEVEL; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FLU LIKE SYNDROME; HEADACHE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TRANSDERMAL DRUG ADMINISTRATION; URINE LEVEL;

ADMINISTRATION, CUTANEOUS; ADULT; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 0032911772     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980050159     Document Type: Article

References (22)

1. Jensen GF, Boesen J, Hedegius V, Transbol I. Epidemiology of postmenopausal spinal and long bone fractures. Clin Orthop 1982;166:75-81.
2. Christiansen C. Skeletal osteoporosis. J Bone Miner Res 1993;8:S475-80.
3. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997;103:3-8S.
4. Heaney RP, Recker RR, Seville PD. Menopausal changes in bone remodeling. J Lab Clin Med 1978;92:964-70.
5. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038-41.
6. Christiansen C, Christiansen MS, McNair P, Hagen C, Stocklund KE, Transbol I. Prevention of early postmenopausal bone loss: controlled 2-year study of 315 normal females. Eur J Clin Invest 1980;10:273-9.
7. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
8. Naessén T, Persson I, Adami H-O, Bergstrom R, Bergkvist L. Hormone replacement therapy and risk of first hip fracture: a prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
9. Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos Int 1997;7(Suppl 1):S3-7.
10. Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561-82.
11. Miller-Bass K, Adashi EY. Current Status and future prospects of transdermal estrogen replacement therapy. Fertil Steril 1990;53:961-74.
12. Adami S, Suppi R, Bertoldo F, et al. Transdermal estradiol in the treatment of post-menopausal bone loss. Bone Miner 1989;7:79-86.
13. Ribot C, Tremollieres F, Pouilles JM. Preventive effects of transdermal administration of 17β-estradiol on post-menopausal bone loss: a 2-year prospective study. Obstet Gynecol 1990;75:42-6.
14. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebocontrolled trial. Am J Obstet Gynecol 1993;168:114-21.
15. Pornel B, Genazzani AR, Costes D, Dain MP, Lelann L, Vandepol C. Efficacy and tolerability of Menorest® 50 compared with Estraderm TTS® 50 in the treatment of postmenopausal symptoms: a randomized, multicenter, parallel group study. Maturitas 1995;22:207-18.
16. Wren B. Menorest®: a clinical overview. Int J Gynaecol Obstet 1996;52(Suppl 1):S27-9.
17. Tamhane AC, Hochberg Y, Dunnet CW. Multiple test procedures for dose finding. Biometrics 1996;52:21-37.
18. Evans SF, Davie MWJ. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 1996;44:79-84.
19. Christiansen C, Christiansen MS, Transbol IB. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61.
20. Genant HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol 1989;161:1842-6.
21. Studd JW, Holland EF, Leather AT, Smith RN. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994;101:787-91.
22. Riggs BL, Melton LJ. Medical progress series: involutional osteoporosis. N Engl J Med 1986;314:1676-86.